Prevalence and burden of dyspnoea among COPD patients in Japan

Background and AimsDyspnoea is the most common symptom of chronic obstructive pulmonary disease (COPD) significantly affecting activity, impairing patients' well-being and contributing to the economic burden of COPD. The objective of this study was to estimate the prevalence of dyspnoea and its impact on COPD management costs in Japan. MethodsA cross-sectional survey was conducted among 82 internal medicine physicians and 85 respiratory specialists representing 420 patients with COPD in Japan. Information was collected on demographic and clinical characteristics, dyspnoea (mMRC scale), and healthcare resource use. Dyspnoea prevalence was estimated among all patients and those on specific COPD treatments. The economic burden was derived from two cohorts based on their level of dyspnoea that were matched by propensity scores balancing their demographic and disease burden characteristics. ResultsModerate-severe dyspnoea (mMRC score 2) was reported by 37.5% of COPD patients and ranging from 21.5% among patients treated with a mono bronchodilator to 59.8% among patients treated with triple therapy. Descriptive analysis showed that dyspnoeic patients have higher annual costs attributable to consultations (Euro2999 vs. Euro1906), medications (Euro1139 vs. Euro716), exacerbations (Euro674 vs. Euro36), other resources (Euro1789 vs. Euro140) and in total (Euro6348 vs. Euro2797) (p < 0.0001 for all comparisons) compared to patients with mild or no dyspnoea (mMRC score < 2). The total costs remained significantly higher in a propensity-matched cohort adjusted for severity and cardiovascular comorbidity [Euro6776.1 vs. Euro4461.3, p = 0.0236]. ConclusionModerate-severe dyspnoea is common among consulting COPD patients in Japan and is a significant cost driver for the healthcare system.